A potent adjuvant effect of CD40 antibody attached to antigen

被引:50
作者
Barr, TA [1 ]
McCormick, AL [1 ]
Carlring, J [1 ]
Heath, AW [1 ]
机构
[1] Univ Sheffield, Sch Med, Div Genom Med, Acad Unit Infect & Immun, Sheffield S10 2RX, S Yorkshire, England
关键词
D O I
10.1046/j.1365-2567.2003.01634.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is great potential for novel vaccines based on recombinant proteins and synthetic peptides. Unfortunately these antigens often lack the immunogenicity of whole, killed pathogens used in traditional vaccines. Thus there is strong interest in the identification of immunological adjuvants with low reactogenicity, but high potency, to enhance immune responses and realize the potential of these new vaccine strategies. CD40 antibodies have been shown to have adjuvant effects when administered at very high doses. These large doses are impractical and induce a cascade of cytokine release giving rise to septic shock-like symptoms, as well as splenomegaly and polyclonal antibody production. We show here that a very small amount of CD40 antibody can exhibit potent adjuvant effects when attached to soluble antigen. The lack of detectable systemic effects indicates that this method may be a powerful and practical means of enhancing the efficacy of recombinant vaccines.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 33 条
[1]  
[Anonymous], VACCINE DESIGN SUBUN
[2]  
Baiu DC, 1999, J IMMUNOL, V162, P3125
[3]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[4]   Enhanced in vivo immune responses to bacterial lipopolysaccharide by exogenous CD40 stimulation [J].
Barr, TA ;
Heath, AW .
INFECTION AND IMMUNITY, 1999, 67 (07) :3637-3640
[5]   Functional activity of CD40 antibodies correlates to the position of binding relative to CD154 [J].
Barr, TA ;
Heath, AW .
IMMUNOLOGY, 2001, 102 (01) :39-43
[6]   ADJUVANT-FREE IGG RESPONSES INDUCED WITH ANTIGEN COUPLED TO ANTIBODIES AGAINST CLASS-II MHC [J].
CARAYANNIOTIS, G ;
BARBER, BH .
NATURE, 1987, 327 (6117) :59-61
[7]   Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials [J].
Corey, L ;
Langenberg, AGM ;
Ashley, R ;
Sekulovich, RE ;
Izu, AE ;
Douglas, JM ;
Handsfield, HH ;
Warren, T ;
Marr, L ;
Tyring, S ;
DiCarlo, R ;
Adimora, AA ;
Leone, P ;
Dekker, CL ;
Burke, RL ;
Leong, WP ;
Straus, SE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04) :331-340
[8]  
de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P3216
[9]   C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity [J].
Dempsey, PW ;
Allison, MED ;
Akkaraju, S ;
Goodnow, CC ;
Fearon, DT .
SCIENCE, 1996, 271 (5247) :348-350
[10]   CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy [J].
Diehl, L ;
den Boer, AT ;
Schoenberger, SP ;
van der Voort, EIH ;
Schumacher, TNM ;
Melief, CJM ;
Offringa, R ;
Toes, REM .
NATURE MEDICINE, 1999, 5 (07) :774-779